Fourth Published Clinical Trial Confirms Long-Term Safety of NIAGEN® Supplementation at High Doses and...

IRVINE, Calif., July 11, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an integrated, science-based, nutraceutical company devoted to improving the way people age, announced today that results from...

TRU NIAGEN® to be featured at the American Society for Nutrition’s Annual Meeting

Tailwinds' Take: CDXC stock has been weak with a combination of lack of news and forecasted sales not picking up until Q3 weighing on...

With Earnings Season Over, Which Stocks Surprised Us?

Quarterly earnings season is the four times each year in which companies give investors an inside look as to what's going on. They not...

ChromaDex Appoints Nobel Laureate, Professor Sir John Walker, to the Scientific Advisory Board

Tailwinds' Take: expect a lot more work to be done around Alzheimer's with the help of this leading researcher.  RVINE, Calif., May 14, 2018 (GLOBE NEWSWIRE) -- ChromaDex...

Recapping This Week’s Earnings, and How Tailwinds Is Playing Each Stock

Many companies in the Tailwinds (TW) coverage universe reported earnings this last week. Here we discuss each of their results (alphabetically), along with a...

ChromaDex Corporation Reports First Quarter 2018 Financial Results

Tailwinds' Take: this is not a shocking number, but would have liked them to guide to growth resuming sooner. We had trimmed after the...

ChromaDex Appoints Frank Jaksch As Executive Chairman, Rob Fried as Chief Executive Officer and...

Tailwinds' Take: Not a surprise that Jaksch moves out of the CEO role as this morphs into a consumer company. Fried is an experienced...

ChromaDex Meeting Notes

I had the opportunity to stop by the offices of ChromaDex (CDXC) last week in LA. It was a beautiful day in LA and...

New Published Clinical Trial Confirms NIAGEN® Supplementation Raised Nicotinamide Adenine Dinucleotide (NAD) Levels and...

Tailwinds' Take: this study reached easily reached the primary endpoint of demonstrating that Niagen increases NAD+ levels. Importantly, the cardiovascular data shows that it...

Chromadex is Data Dependent…Boulder Study Coming Soon

Shares of Chromadex are not cheap. When you look at this company relative to sales, the $200+ million market cap sticks out like a...

ChromaDex Corporation Reports 2017 Financial Results

IRVINE, Calif., March 08, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corporation (NASDAQ:CDXC), a science-based, integrated nutraceutical company devoted to improving the way people age, announced today fourth quarter and...

Why I Tell My Friends to Take Niagen

Thanks to a recent article in Time Magazine, Nicotinamide Riboside and NAD replenishment are getting a lot of attention. Because I have been taking NR...

Two Additional Collaborative Human Studies on NIAGEN® with the University of Cambridge and the...

Tailwinds' Take: with nearly 140 trials underway involving Niagen, CDXC has more than its share of catalysts coming in the near future. These two...

CDXC Seller Revealed in Filings

One of our top picks, Chromadex shares have been under pressure over the last few months. The shares hit a high of around $7...

ChromaDex Corporation Reports Preliminary 2017 Results

Tailwinds' Take: Revenue exceeded Company and Wall Street forecasts. Singapore launch coming in Q1. Well positioned for a huge 2018. IRVINE, Calif., Feb. 12, 2018 (GLOBE NEWSWIRE)...

Compound prevents neurological damage, shows cognitive benefits in mouse model of Alzheimer’s disease

Tailwinds' Take: yet another positive study result for what will surely become a blockbuster supplement. CDXC stock has traded well off its highs. Great...

Elysium Health, Inc. Challenge of ChromaDex Licensed Patent Denied by Patent Trial and Appeal...

Tailwinds' Take: while not unexpected, a very important win for CDXC, which takes away the biggest potential concern for the Company.  IRVINE, Calif., Jan. 22, 2018 (GLOBE...

ChromaDex and Watsons Expand Partnership with TRU NIAGEN™ Retail Launch in Singapore

Tailwinds' Take: based on their "successful", to quote the Company, launch in Hong Kong, this is probably the first of several more markets that...

Previewing 2018…What to Expect From Our Portfolio

As we enter the new year it is very difficult not to be optimistic...borderline exuberant. The Tailwinds Select Portfolio has been on a tear...

Published Study Reveals NIAGEN® Nicotinamide Riboside is an Effective NAD Precursor to Protect Cardiac...

Tailwinds' Take: the implications of this study are potentially massive. It truly appears that NR has many positive effects and is well on its...